Colm Farrell results 3
· Newest (Page 1/1, per page 25)
Author: Colm Farrell ×Clear All Filters
Search Results
Population pharmacokinetics and exposure–response relationships of maribavir in transplant recipients with cytomegalovirus infectionNARA Subscribed
Maribavir is approved for management of post-transplant cytomegalovirus (CMV) infections refractory and/or resistant to CMV therapies at a dose of 400 mg twice daily (BID). Population pharmacokinetic (PopPK) and exposure–response analyses were conducted to support the appropriateness of 400 mg BID dosing. A PopPK model was developed using non-linear mixed-effects modeling with pooled maribavir plasma concentration–time data fr...
Previous1Next